Note 2 - Acquisitions and Divestitures (Details Textual) $ in Thousands, € in Millions							3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Oct. 11, 2019 USD ($)	Jul. 12, 2019 USD ($)	Oct. 22, 2018 USD ($)	Oct. 22, 2018 EUR (€)	Sep. 20, 2018 USD ($)	Apr. 05, 2018 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2019	Oct. 22, 2018 EUR (€)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life										10 years 36 days
Reddick Divestiture [Member]
Proceeds from Sale of Productive Assets, Total						$ 7,400
Long-term Purchase Commitment, Period						2 years
Gain (Loss) on Disposition of Assets for Financial Service Operations, Total									$ 5,900
CardioCel and VascuCel Biologic Patches [Member]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual							$ 1,400
Payments to Acquire Businesses, Gross	$ 14,200
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period	15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years 146 days
CardioCel and VascuCel Biologic Patches [Member] | Achieving Audited Financial Statements of Acquired Business [Member]
Payments to Acquire Businesses, Gross	$ 300
CardioCel and VascuCel Biologic Patches [Member] | First Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	700
CardioCel and VascuCel Biologic Patches [Member] | Second Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	700
CardioCel and VascuCel Biologic Patches [Member] | Third Holdback [Member]
Business Combination, Contingent Consideration, Liability, Total	2,000
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Twenty Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	2,500
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Fifteen Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	1,200
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Thirty Million in the Second Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	2,500
CardioCel and VascuCel Biologic Patches [Member] | Revenues Exceeding Twenty-Two and a Half Million in the First Twelve Month Period After Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	1,200
CardioCel and VascuCel Biologic Patches [Member] | Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]
Business Combination, Contingent Consideration, Liability, Total	500
CardioCel and VascuCel Biologic Patches [Member] | Technology Licenses [Member]
Business Combination, Consideration Transferred, Total	8,000
CardioCel and VascuCel Biologic Patches [Member] | Maximum [Member] | Biological Patch Business Assets [Member]
Business Combination, Consideration Transferred, Total	$ 15,300
Tru-Incise Valve Cutter [Member]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								$ 800
Business Combination, Consideration Transferred, Total		$ 8,000
Payments to Acquire Businesses, Gross		$ 6,800
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period		15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		11 years 292 days
Business Combination, Deferred Purchase Consideration, Installment Payment		$ 400
Business Combination, Deferred Purchase Consideration		1,200
Acquisition Date Fair Value		$ 1,100
Business Combination ,Fair Value Inputs, Discount Rate		4.19%
Cardial [Member]
Business Combination, Consideration Transferred, Total			$ 2,300	€ 2.0
Payments to Acquire Businesses, Gross			$ 1,300	€ 1.1
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			9 years 146 days	9 years 146 days
Business Combination, Deferred Purchase Consideration			$ 400								€ 0.4
Business Combination, Consideration Transferred, Liabilities Incurred			500	€ 0.5
Deferred Tax Assets, Business Combinations			600								€ 0.5
Business Combination, Bargain Purchase, Gain Recognized, Amount			$ 1,600	€ 1.4
Applied Medical [Member]
Business Combination, Consideration Transferred, Total					$ 14,200
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period					15 years
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life					13 years
Acquisition Date Fair Value					$ 3,043
Business Combination ,Fair Value Inputs, Discount Rate					3.75%
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Deferred Costs					$ 3,200
Applied Medical [Member] | UNITED STATES
Percentage of Sales by Major Product Lines					60.00%
Applied Medical [Member] | Foreign [Member]
Percentage of Sales by Major Product Lines					40.00%
Applied Medical [Member] | Closing Date [Member]
Business Combination, Consideration Transferred, Total					$ 11,000
Applied Medical [Member] | 12 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					2,000
Applied Medical [Member] | 24 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total					$ 1,200
Balloon Supply Agreement [Member] | Reddick Divestiture [Member]
Long-term Purchase Commitment, Period						6 years